
-
Jazz Pharmaceuticals NasdaqGS:JAZZ Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Location: Waterloo Exchange, Dublin, D04 E5W7, Ireland | Website: https://www.jazzpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
9.52B
Cash
2.572B
Avg Qtr Burn
N/A
Short % of Float
9.97%
Insider Ownership
2.86%
Institutional Own.
99.90%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Xywav (JZP-258) (oxybate salts) Details EDS in Idiopathic Hypersomnia
| Approved Quarterly sales | |
EPIDIOLEX® (cannabidiol) Details Epilepsy, Dravet syndrome, Tuberous sclerosis complex, Lennox-Gastaut syndrome | Approved Quarterly sales | |
Zepzelca (Lurbinectedin) Details Cancer, Small cell lung cancer | Approved Quarterly sales | |
Ziihera® (zanidatamab-hrii) Details Cancer, HER2-expressing cancers, Biliary Tract Cancer | Approved Quarterly sales | |
Rylaze /Enrylaze (JZP-458) Details Acute lymphoblastic leukemia | Approved Quarterly sales | |
Zanidatamab + chemo / trastuzumab +chemotherapy Details Cancer, Breast cancer | Phase 3 Data readout | |
EPIDIOLEX® (cannabidiol) Details Rare diseases, Neurological disorder, Rare genetic disease, Epilepsy, Seizures | Phase 3 Data readout | |
Zanidatamab (HER2) Details Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Zanidatamab combo w/ chemo Details Cancer, HER2-expressing cancers, Gastroesophageal adenocarcinomas | Phase 3 Data readout | |
Zepzelca + atezolizumab (Tecentriq®) Details Extensive-stage small cell lung cancer (ES-SCLC) | Phase 3 Data readout | |
Zepzelca + Irinotecan Details Relapsed small cell lung cancer (SCLC) | Phase 3 Update | |
Suvecaltamide (JZP-385) Details Essential tremor | Phase 2b Update | |
Suvecaltamide (JZP-385) Details Parkinson's disease | Phase 2 Data readout | |
Zepzelca (Lurbinectedin) Details Cancer, Solid tumor/s | Phase 2 Data readout | |
CBDV (Cannabidivarin /GWP42006) Details Epilepsy, Autism spectrum disorders | Phase 2 Data readout | |
Ziihera + chemotherapy Details HER2-positive advanced or metastatic gastroesophageal adenocarcinoma (mGEA) | Phase 2 Data readout | |
Zanidatamab + Palbociclib + Fulvestrant Details Cancer, ER+/HER2- breast cancer | Phase 2a Data readout | |
Zepzelca (Lurbinectedin) Details Solid tumor/s, Cancer, Endometrial cancer | Phase 1/2 Data readout | |
Zepzelca (Lurbinectedin) w/ ipilimumab and nivolumab Details Cancer, Soft tissue sarcoma | Phase 1/2 Data readout | |
Zanidatamab combo w/ docetaxel Details Cancer, HER2-expressing cancers | Phase 1/2 Interim update | |
JZP351 (CPX-351) Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 1b Data readout | |
JZP815 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Zanidatamab Details Cancer, Breast cancer | Phase 1 Data readout | |
JZP441 (orexin-2 receptor agonist) Details Sleeping disorder, EDS in Idiopathic Hypersomnia
, Narcolepsy | Phase 1 Update | |
JZP898 Details Solid tumor/s, Cancer | Phase 1 Initiation | |
EPIDIOLEX® (cannabidiol) Details Rare diseases, Rare genetic disease, Rett syndrome, Neurological disorder | Failed Discontinued | |
JZP-150 (FAAH inhibitor) Details Post-traumatic stress disorder | Failed Discontinued | |
Nabiximols Details Multiple sclerosis | Failed Discontinued |